Latest News for: her2

Edit

Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration

Victoria Advocate 17 Apr 2025
In the preliminary findings of a study conducted with the National Taiwan University Hospital, over 50% of sample cases were reclassified as HER2-expressing when 3D pathology was applied ....
Edit

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs ...

Business Wire 10 Apr 2025
... for OST-HER2 combined palliative radiation in dogs with unresected appendicular osteosarcoma.
Edit

Trastuzumab deruxtecan approved to treat adults with HER2-positive cancer that has spread or cannot be removed by surgery (MHRA - Medicines and Healthcare products Regulatory Agency)

Public Technologies 09 Apr 2025
... metastatic HER2-positive breast cancers, who have received two or more prior anti-HER2-based regimens for non-small cell lung cancer with an activating HER2 mutation and HER2-postivie gastric cancer.
Edit

DATROWAY� Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative ...

Business Wire 08 Apr 2025
TOKYO & MUNICH--(BUSINESS WIRE)--DATROWAY� (datopotamab deruxtecan) has been approved in the ...
Edit

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

The Milton Standard Journal 07 Apr 2025
BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / ...
Edit

ENHERTU� Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, ...

Business Wire 04 Apr 2025
TOKYO & MUNICH--(BUSINESS WIRE)--ENHERTU� Approved in the EU as 1st HER2 Directed Therapy for Patients with HR+, HER2 Low or HER2 Ultralow mBC Following at Least 1 Endocrine Therapy ... .
Edit

Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy (Form 6-K) (AstraZeneca plc)

Public Technologies 04 Apr 2025
With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer, and are exploring its potential in ...
Edit

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced ...

Enid News & Eagle 31 Mar 2025
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Mar 31, 2025-- ... .
Edit

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

The Galveston Daily News 31 Mar 2025
NEW YORK--(BUSINESS WIRE)--Mar 31, 2025-- ....
Edit

DESTINY-Gastric05 Phase 3 Trial of ENHERTU� Initiated in Patients with Previously Untreated HER2 Positive Advanced ...

Business Wire 31 Mar 2025
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DESTINY-Gastric05 Phase 3 Trial of ENHERTU� Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ... .
  • 1

Article Search

tools
×
×
×
×